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a  b  s  t  r  a  c  t
Ammonium  2,3,3,3-tetraﬂuoro-2-(heptaﬂuoropropoxy)-propanoate,  developed  for use  as a  polymeriza-
tion processing  aid  in the  manufacture  of ﬂuoropolymers,  was  tested  for  its  potential  chronic  toxicity
and  carcinogenicity  in  a 2-year  oral  dosing  study  in  Sprague–Dawley  rats. Male  rats  were  given  daily
doses  of  either  0,  0.1,  1  or 50 mg/kg;  females  were  given  either  0,  1, 50 or  500  mg/kg.  Body  weights,  food
consumption  and  clinical  signs  were  monitored  daily;  clinical  pathology  was  conducted  at  designated
intervals  and  animals  were given  a complete  pathological  evaluation  after  12 months  and  24 months  of
dosing.  Normal  survival  was  seen  in  all groups,  no abnormal  clinical  signs  were  seen,  and  body  weight
gain  was  reduced  only  in  female  rats  at 500  mg/kg.  Both  sexes  at the  high  dose  had  mild  decreases  in
red  cell  mass  which  were  somewhat  more  pronounced  in females.  Clinical  pathology  indicative  of  liver
injury  was present  in males  that  received  50 mg/kg  and  correlated  with  histomorphological  liver changes
that  included  both  hypertrophic  and  degenerative/necrotic  lesions.  Similar  histomorphological  lesions
were  seen  in the  livers  of  females  at 500  mg/kg.  Previous  shorter  term toxicity  studies  have  identiﬁed
this  chemical  as a PPAR  agonist  and  the  ﬁnding  of  benign  tumors  of  the  liver,  pancreas  and/or  testes  in
males  at  50  mg/kg  and  females  at 500  mg/kg  is  consistent  with  the  rat  response  to peroxisome  prolifera-
tors  and is  of  questionable  human  relevance.  Changes  in the  kidney,  tongue,  and  stomach  were  observed
only  at  the  highest  dose  of  500  mg/kg  in  females.  The  no-observed-adverse-effect-level  in this  study  lies
between  1  and  50 mg/kg  for  males  and  between  50 and  500  mg/kg  for females.
©  2015  The  Authors.  Published  by  Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the  CC  BY. Introduction
Ammonium 2,3,3,3-tetraﬂuoro-2-(heptaﬂuoropropoxy)-
ropanoate (CAS 62037-80-3) is a white/colorless solid with
 sublimation point of 130–140 ◦C, a decomposition point of
50–160 ◦C, a density of approximately 1.7 g/cm3 at 20 ◦C, and a
ery low vapor pressure of approximately 0.01 Pa at 20 ◦C [10].
he chemical has been developed for use as a polymerization
rocessing aid in the manufacture of ﬂuoropolymers. The acute
oxicity proﬁle includes both an oral LD50 of 1750 and 3129 mg/kg
n male and female rats, respectively, and 1030 mg/kg in mice
females). The dermal LD50 in rats is greater than 5000 mg/kg. By
he inhalation route, the chemical has an acute LC50 of greater
∗ Corresponding author. Tel.: +1 3024514591.
ttp://dx.doi.org/10.1016/j.toxrep.2015.06.001
214-7500/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access license  (http://creativecommons.org/licenses/by/4.0/).
than 5200 mg/m3 in rats exposed for 4 h. As tested in rabbits, it
is highly irritating to the eye but is not a skin irritant nor is it a
sensitizer as tested by the mouse local lymph node assay. The
material is not genotoxic based on a battery of tests including
Ames and chromosome aberration in-vitro studies and mouse
micronucleus, mouse bone marrow chromosomal analysis and rat
unscheduled DNA synthesis in-vivo studies [10].
The compound is rapidly and completely absorbed following
oral administration in both rats and mice, is not metabolized, and
is eliminated almost exclusively in the urine. In the cynomolgus
monkey given a single intravenous dose, the chemical was  rapidly
eliminated, no sex differences were seen, and a biphasic pattern
of elimination was  present. Based on oral studies in rats and mice,
and intravenous studies in rats and primates, elimination of the
test substance is most similar and more rapid in primates and rats,
with mice having a comparatively longer clearance time. Clearance
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imes in rats and primates are generally less than 12–24 h while
hose in mice are 60–140 h. Plasma elimination kinetics were simi-
ar following both single and multiple dose studies indicating a low
ropensity for accumulation in the body. Based on the pharmacoki-
etic curve following an intravenous dose of the compound, male
ats have a slightly slower elimination rate than females, resulting
n males having a higher plasma concentration than females after
he same dose [11].
In repeated dose toxicity studies, the test material induces hep-
tic peroxisomal -oxidation activity and produces microscopic
hanges in the livers of rodents consistent with the activity of
eroxisome proliferators. Thus, the test material is a member of
 class of compounds known as PPAR agonists, which include
ndogenous long chain fatty acids, as well as many industrial chem-
cals and pharmaceuticals. These compounds produce effects in the
iver to which rodents have been shown to be more sensitive than
ther species, including humans. In a series of repeated oral dos-
ng studies of 28–90 days duration in rats and mice, the sentinel
ffects of this chemical were consistent with those of a PPAR ago-
ist [12,13]. These included increased liver beta-oxidation activity,
ncreased liver weights, microscopic hepatocellular hypertrophy,
nd clinical pathology changes of decreases in red cell parameters,
hanges in serum proteins, and decreases in serum lipids.
Speciﬁcally, in a 90-day repeated dose toxicity study in which
ale rats were given daily gavage doses of either 0.1, 10, or
00 mg/kg, ﬁndings included most of the clinical pathology and
natomic pathology effects noted above, as well as increased kid-
ey weights [13]. Similar ﬁnding were seen in female rats given
aily gavage doses of either 10, 100, or 1000 mg/kg. These included
idney weight increases at 10 mg/kg, PPAR-related clinical chem-
stry changes at 100 mg/kg, and red blood cell effects, increased
iver weights, and hepatocellular hypertrophy at 1000 mg/kg. Find-
ngs similar to these were seen in an earlier 28-day dosing study
ith liver effects seen in males following dosing at 3 mg/kg and
n females at 300 mg/kg [12]. These studies formed the basis for
ose level selection for the chronic toxicity/carcinogenicity study
eported here.
To characterize the chronic toxicity proﬁle and to evaluate the
otential carcinogenic effects of this chemical, a 2-year chronic tox-
city and carcinogenicity study was conducted in rats. This paper
overs the information derived from this experiment. The results of
his study are reported herein and will be compared to those found
n other chronic/carcinogenicity studies with similar ﬂuorochemi-
als to place the ﬁndings in perspective.
. Materials and methods
.1. Chemicals
The ammonium salt of 2,3,3,3-tetraﬂuoro-2-
heptaﬂuoropropoxy)-propionic acid (84%; CAS number
2037-80-3; C6H4F11NO3; molecular weight: 347) was  pro-
ided by E.I. du Pont de Nemours and Company (Wilmington,
E). The test article was an 84% aqueous solution and doses were
djusted accordingly and are expressed in terms of 100% test
hemical. Formulations of the test article were prepared weekly
nd stored at room temperature.
.2. Animals
All rat treatments, toxicity assessments and data acquisitions
ere performed at MPI  Research, Inc. (Mattawan, Michigan). The
rotocol was reviewed and approved by the Institutional Animal
are and Use Committee (IACUC), in compliance with the Animal
elfare Act (AWA). Male and female CD® [Crl:CD(SD)] rats were Reports 2 (2015) 939–949
received at approximately 5 weeks of age from Charles River Labo-
ratories (Portage, Michigan). Rats were acclimated for 14 days prior
to being randomly assigned to treatment groups using a standard,
by weight, measured value randomization procedure. Rats assigned
to study had body weights within ±20% of the mean body weight
for each sex. The animals were pair-housed (same sex) in polyboxes
with non-aromatic bedding in an environmentally-controlled room
and were provided environmental enrichment. All animals were
maintained in accordance with the Guide for the Care and Use of
Laboratory Animals in the animal facilities at MPI  Research, Inc.
(American Association for the Accreditation of Laboratory Animal
Care [AAALAC] accredited). Block Lab Diet® (Certiﬁed Rodent Diet
#5002, PMI  Nutrition International, Inc., Shoreview, MN, USA) was
provided ad libitum. Tap water was  available ad libitum via an auto-
matic watering system. Room temperature and humidity controls
were maintained to the maximum extent possible between 64 and
79 ◦C and 30–70%, respectively. A 12 h light/dark photoperiod was
maintained.
2.3. Treatment
Four treatment groups of 80 rats/sex were formed. Control
group males and females received deionized water (vehi-
cle control). Male rats in test groups received either 0.1, 1
or 50 mg  ammonium 2,3,3,3-tetraﬂuoro-2-(heptaﬂuoropropoxy)-
propanoate/kg body weight/day. Female rats in test groups
received either 1, 50 or 500 mg  ammonium 2,3,3,3-tetraﬂuoro-
2-(heptaﬂuoropropoxy)-propanoate/kg body weight/day. Ten ani-
mals/sex/group were designated for the 12 month interim
necropsy. The remaining surviving animals were designated for the
terminal necropsy.
Dose selection was  based on a previous subchronic (90-day) tox-
icity study [13] and a previous 28-day study [12]. The vehicle and
test article were administered once daily for up to 104 weeks in
males and up to 101 weeks in females via oral gavage at a dose
volume of 10 mL/kg/dose. The control group received the vehicle
in the same manner as the treated groups. Individual doses were
based on the most recent body weights. All animals were observed
for morbidity, mortality, injury, and availability of food and water
twice daily. Beginning at week 53, a third daily cageside observation
was added. A detailed clinical examination, including a physical
exam and palpation of masses, was  performed weekly. Ophthalmo-
scopic examinations were conducted on all animals pretest and on
all surviving animals prior to the interim and terminal necropsies.
2.4. Body weight and food consumption
Body weights were recorded weekly starting day 1 (prior to dos-
ing) until week 14, and then every two  weeks thereafter. Body
weight changes were calculated and reported weekly the ﬁrst 3
months (weeks 1–13), the ﬁrst year (weeks 1–52), and for the entire
study (weeks 1–102 for males and weeks 1–100 for females). Food
consumption was  recorded pretest (week – 1), weekly during the
ﬁrst 13 weeks, and then every two  weeks starting on week 14. Food
consumption was measured for the cage and divided by the num-
ber of surviving animals. Food consumption and efﬁciency were
calculated weekly the ﬁrst 3 months (weeks 1–13), the ﬁrst year
(weeks 1–52), and for the entire study (weeks 1–102 for males and
weeks 1–100 for females).
2.5. Clinical pathologyClinical pathology evaluations were conducted on 10 ani-
mals/sex/group at 3, 6 and 12 months (hematology and clinical
chemistry) and 10 animals/sex/group at 6 and 12 months (coag-
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elected for bleeding and these same animals were used for all
ime points. Blood samples were collected via the vena cava or car-
iac puncture after carbon dioxide inhalation. The order of bleeding
as by alternating 1 animal from each dose group then repeating
o reduce handling and time biases. Blood samples for peripheral
lood smears were collected at 12 and 18 months and prior to ter-
inal necropsy. The animals designated for a full clinical pathology
valuation had access to drinking water but were fasted overnight
rior to scheduled sample collection. The animals designated for
nly blood smears had access to drinking water and food prior to
ample collection. Urine was collected after animals were housed
n stainless steel metabolism cages for at least 12 h.
Hematology parameters evaluated included: leukocyte count
total and absolute differential), erythrocyte count, hemoglobin,
ematocrit, mean corpuscular hemoglobin, mean corpuscular vol-
me, mean corpuscular hemoglobin concentration (calculated),
bsolute reticulocytes, platelet count, and platelet morphology.
oagulation parameters evaluated included prothrombin time and
ctivated partial thromboplastin time.
Clinical chemistry parameters evaluated included alanine
minotransferase, alkaline phosphatase, sorbitol dehydrogenase,
otal protein, albumin, globulin and A/G (albumin/globulin) ratio
calculated), urea nitrogen, creatinine, total cholesterol, triglyc-
rides, total bilirubin (with direct bilirubin if total bilirubin
xceeded 1 mg/dL), aspartate aminotransferase, total bile acids,
lucose, calcium, phosphorus, electrolytes (sodium, potassium and
hloride), and gamma glutamyl transferase.
Urinalysis parameters evaluated included volume, speciﬁc grav-
ty, pH, color and appearance, protein, glucose, bilirubin, ketones,
lood, urobilogen, and microscopy of centrifuged sediment.
.6. Necropsy and histopathological evaluation
Postmortem study evaluations were performed on all animals
uthanized in extremis, animals found dead, and on all surviv-
ng animals scheduled and sacriﬁced at the interim (12 months)
nd terminal (101 and 104 weeks – approximately 24 months)
ecropsies. The animals were euthanized by carbon dioxide inhala-
ion followed by exsanguination via the abdominal vena cava. At
ecropsy, external surfaces and abdominal, thoracic, and cranial
avities were examined for abnormalities including masses. Tissues
rom all organ systems (digestive, urinary, respiratory, cardio-
ascular, hematologic, nervous, endocrine, musculoskeletal, and
eproductive systems, as well as skin and gross observations) were
emoved, examined, and, where required by protocol, placed in ﬁx-
tive (neutral buffered formalin, except for the eye [including the
etina and optic nerve] and testes, which were ﬁxed using a mod-
ﬁed Davidson’s ﬁxative). Body weights and organ weights (brain,
drenals, heart, kidneys, liver, spleen, thyroid/parathyroid, and/or
pididymides, testes, ovaries with oviducts, and uterus with cervix)
ere recorded for all surviving animals at the scheduled necrop-
ies and appropriate organ weight ratios were calculated (relative
o body and brain weights). Paired organs were weighed together.
icroscopic examination of ﬁxed hematoxylin and eosin-stained
arafﬁn sections was performed on tissues by a board-certiﬁed
eterinary pathologist. A four-step grading system was utilized to
eﬁne gradable lesions for comparison between dose groups. For
atal and incidental neoplasms, the onset date was considered to be
he fate date of the affected animal. For mortality independent neo-
lasms, the onset date was considered to be the ﬁrst appearance
f a related abnormality (e.g., abrasion, nodule, and/or swelling). A
econd board-certiﬁed pathologist performed a formal peer review
f the histopathological ﬁndings and the results reported here rep-
esent the consensus. Reports 2 (2015) 939–949 941
2.7. Statistical analysis
For continuous data (body weight and weight gain, food con-
sumption, hematology, coagulation, clinical chemistries, and organ
weights), the statistical procedures were generally as follows: Lev-
ene’s test [20] was used to assess homogeneity of group variances
for each speciﬁed endpoint and for all collection intervals. If Lev-
ene’s test was  not signiﬁcant (p > 0.01), a pooled estimate of the
variance (mean square error) was  computed from a one-way anal-
ysis of variance (ANOVA) and utilized by a Dunnett’s comparison
[9] of each treatment group with the control group. If Levene’s test
was signiﬁcant (p < 0.01), comparisons with the control group were
made using Welch’s t-test [28] with a Bonferroni correction.
Intercurrent mortality data were analyzed using the
Kaplan–Meier product-limit method. An overall test compar-
ing all groups was conducted using a log-rank test [2]. Tumor
incidence data were analyzed using both survival adjusted and
unadjusted tests. The Cochran–Armitage trend test [1] was  cal-
culated and Fisher’s exact test [29] was used to compare each
treatment group with the control group. The survival adjusted test
was conducted according to the prevalence/mortality methods
described by Peto et al. [24].
All endpoints were analyzed using two-tailed tests with results
of all pair-wise comparisons reported at the 0.05 and 0.01 signiﬁ-
cance levels.
3. Results
This experiment was conducted in accord with the Toxic Sub-
stance Control Act (TSCA) Good Laboratory Practice Standards. All
system suitability tests, performance checks, and calibration stan-
dards met  analysis acceptance criteria and the dose formulation
samples, analyzed for homogeneity and concentration, met the cri-
teria for acceptance based on accuracy and precision. On quality
assurance check, no signiﬁcant deviations from the protocol which
could impact the quality or integrity of the study were found.
3.1. Survival
Mean survival data for male and female rats are illustrated in
Fig. 1. The test substance had no effect on survival. Females were
sacriﬁced during week 101, prior to scheduled termination at week
104, due to low survival in all female dose groups (especially con-
trol and 50 mg/kg groups). However, even though survival among
all female groups was  low, there were no statistically signiﬁcant
differences between groups as survival was  essentially the same.
Seven of the 500 mg/kg early death females had test substance-
associated papillary necrosis and inﬂammation of the kidney. All
other causes of death/morbidity were considered incidental and
common in rats of this strain and age.
3.2. In-life observations
There were no test substance-related clinical observations; all
observations were transient or common in this species. In addi-
tion, there were no test substance-related increases in masses
identiﬁed during physical examination nor were there any test
substance-related ﬁndings at the interim or terminal ophthalmo-
scopic examinations.
The test substance had no effect on body weight, body weight
gain, or food consumption and efﬁciency in males. These values
were generally comparable to those of control animals throughout
the study.
Exposure of female rats to 500 mg/kg produced reductions in
body weight, body weight gain, and food efﬁciency. Mean body
weight for this group was 13% below that for control animals at
942 J.M. Caverly Rae et al. / Toxicology Reports 2 (2015) 939–949
Fig. 1. Kaplan–Meier survival curves for rats treated with ammonium 2,3,3,3-tetraﬂuoro-2-(heptaﬂuoropropoxy)-propanoate for 104 weeks (male) or 101 weeks (female).
(A)  Survival curve of male rats treated with either 0, 0.1, 1 or 50 mg/kg. p > 0.05. (B) Survival curve of female rats treated with either 0, 1, 50 or 500 mg/kg, p > 0.05.




























3ig. 2. Mean body weights for female rats treated with either 0, 1, 50 or 500 mg/kg
eek 52 (statistically signiﬁcant), but was comparable to controls
t study termination (Fig. 2). Consequently, mean body weight gain
as 20% below controls over weeks 1–52 in this group, but only
lightly lower than controls over the entire 2 year study (not sta-
istically signiﬁcant). There were no effects on food consumption;
he reduced body weight gain was associated with lower mean
ood efﬁciency over the ﬁrst year (although food efﬁciency over
he entire 2 year study was comparable to controls).
.3. Clinical pathology
At the 3, 6, and 12 month intervals, the test substance
aused mild but adverse decreases in red cell mass (erythrocytes,
emoglobin, and hematocrit; up to 28% below controls) in females
eceiving 500 mg/kg (Fig. 3). These changes were associated with an
ppropriate increase in reticulocytes (up to 106% above controls).
here were no effects on erythrocyte morphology.
Statistically signiﬁcant decreases in erythrocytes, hemoglobin,
nd hematocrit were also present in males receiving 50 mg/kg at
he 3 and 6 month intervals. However, the decreases were small,
ransient (no statistically signiﬁcant difference at 12 months), and
id not induce a statistically signiﬁcant increase in reticulocytes.
Increases in enzymes indicative of liver injury, including mild
ncreases in alkaline phosphatase, alanine aminotransferase, aspar-
ate aminotransferase, and sorbitol dehydrogenase (aspartate
minotransferase was not statistically signiﬁcant) were observed
t 12 months in males at 50 mg/kg (Fig. 4) and were correlated with
icroscopic ﬁndings of minimal cystic degeneration and minimalo mild focal necrosis in the liver. Minimal increases in alkaline
hosphatase, unassociated with increases in other liver injury-
peciﬁc enzymes, were also present in males at this dose level at
 and 6 months. There were no test article-related liver enzymeonium 2,3,3,3-tetraﬂuoro-2-(heptaﬂuoropropoxy)-propanoate for 101 weeks.
changes in males receiving either 0.1 or 1 mg/kg or in females at
any dose.
Test substance-associated increases in albumin (up to 16%
above controls), decreases in globulin (up to 17% below con-
trols), and increases in the albumin/globulin ratio were present in
males at 50 mg/kg and females at 500 mg/kg at various intervals
with variable statistical signiﬁcance. Albumin was also statis-
tically signiﬁcantly increased in males receiving 1 mg/kg at 12
months (8% above controls) and globulin was  statistically signif-
icantly decreased transiently (only at 6 months, 6% below controls)
in females receiving 50 mg/kg. Minimal, statistically-signiﬁcant
increases in the albumin/globulin ratio were also present in the
1 mg/kg males and the 50 mg/kg females at various intervals.
A minimal diuresis was present at 6 and 12 months in females
that received 500 mg/kg, as evidenced by statistically signiﬁcant
increases in urine volume and decreases in urine speciﬁc gravity.
There were no changes in kidney-related chemistry parameters.
This diuresis may  be correlated to an increase in the incidence and
severity of chronic progressive nephropathy (CPN) observed in this
group at the 1-year sacriﬁce (Table 1).
There were no other test article related clinical pathology
effects. All other mean and individual clinical pathology parame-
ters were considered within an acceptable range for biological and
procedure-related variation.
3.4. Organ weights and anatomic pathology observations
No test-substance associated anatomic pathology ﬁndings
occurred in male rats administered either 0.1 or 1 mg/kg or in
female rats administered either 1 or 50 mg/kg. Test substance-
associated ﬁndings observed in males at 50 mg/kg and in females
at 500 mg/kg are described in Section 3.4.1, 3.4.2 and 3.4.3. All
944 J.M. Caverly Rae et al. / Toxicology Reports 2 (2015) 939–949












(ig. 3. Mean red cell mass parameters for female rats treated with either 0 (control
or  12 months. RBC = erythrocytes (106/L); hemo = hemoglobin (g/dL); HCT = hema
ontrol  (p < 0.01), N = 10.
ther organ weight, macroscopic and non-neoplastic and neoplas-
ic microscopic observations were of the type typically seen in
ats of this strain and age, and were considered incidental and not
elated to compound administration..4.1. Organ weights and macroscopic ﬁndings
At the interim necropsy, test substance-associated organ weight
ffects were limited to increased liver weights (Table 1) in the
0 mg/kg male group (16% above controls relative to body weight)
ig. 4. Selected mean clinical chemistry parameters for male rats treated with either 0 (c
ropanoate for 12 months. Alk Phos = alkaline phosphatase (U/L); ALT = alanine aminotran
U/L).  * = Signiﬁcantly different from control (p < 0.05); # = signiﬁcantly different from con or 500 mg/kg ammonium 2,3,3,3-tetraﬂuoro-2-(heptaﬂuoropropoxy)-propanoate
(%). * = Signiﬁcantly different from control (p < 0.05); # = signiﬁcantly different from
and in the 500 mg/kg female group (69% above controls relative to
body weight). In females, liver weight changes correlated with cen-
trilobular hypertrophy microscopically. In one 500 mg/kg female,
the macroscopic ﬁnding of irregular surface of the kidney correlated
with CPN in this animal and was likely test substance-related.At the terminal sacriﬁce, no test compound-associated organ
weight or macroscopic effects were observed in males. In females,
test substance-associated organ weight changes were limited to
increased liver weights (Table 1) at 500 mg/kg (43% above con-
ontrol), 0.1, 1 or 50 mg/kg ammonium 2,3,3,3-tetraﬂuoro-2-(heptaﬂuoropropoxy)-
sferase (U/L); AST = aspartate aminotransferase (U/L); SDH = sorbitol dehydrogenase
trol (p < 0.01), N = 10.
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Table  1
Mean liver weight parameters for male rats treated with either 0, 0.1, 1 or 50 mg/kg ammonium 2,3,3,3-tetraﬂuoro-2-(heptaﬂuoropropoxy)-propanoate and female rats
treated with either 0, 1, 50 or 500 mg/kg ammonium 2,3,3,3-tetraﬂuoro-2-(heptaﬂuoropropoxy)-propanoate for 12 (interim sacriﬁce) and 24 (terminal sacriﬁce) months.
Mean liver weights at interim and terminal sacriﬁce in male and female rats
Males
Interim sacriﬁce Terminal sacriﬁce
Dose level (mg/kg) 0 0.1 1 50 0 0.1 1 50
N  10 10 10 10 15 20 18 18
Absolute (g) 26.9 ± 4.9* 26.1 ± 4.3 25.5 ± 1.9 29.7 ± 5.0 24.3 ± 3.6 26.6 ± 6.4 24.1 ± 5.6 27.1 ± 4.8
%  −3% −5% 10% 9% −1% 12%
Liver/body weight (%) 3.2 ± 0.3 3.3 ± 0.3 3.3 ± 0.2 3.7 ± 0.4# 2.9 ± 0.4 3.3 ± 1.3 3.2 ± 0.7 3.2 ± 0.5
%  3% 3% 16% 14% 10% 10%
Females
Interim sacriﬁce Terminal sacriﬁce
Dose level (mg/kg) 0 1 50 500 0 1 50 500
N  10 10 10 10 16 22 15 18
Absolute (g) 13.2 ± 2.5 12.0 ± 1.6 14.8 ± 3.6 17.6 ± 2.6# 16.4 ± 3.8 15.8 ± 4.3 17.2 ± 3.0 23.2 ± 8.2#
% −9% 12% 33% −4% 5% 41%
Liver/body weight (%) 2.9 ± 0.3 3.0 ± 0.3 3.3 ± 0.4 4.9 ± 0.6# 3.5 ± 0.4 3.3 ± 0.7 3.3 ± 0.6 5.0 ± 0.9#







































c# Signiﬁcantly different from control (p < 0.01). %Indicates difference from contro
* Mean ± standard deviation.
rols relative to body weight). Macroscopic ﬁndings in this group
ncluded tan focus/foci in the liver (8/70 versus 1/70 in controls),
ass/nodule in the liver (14/70 versus 0/70 in controls) and irregu-
ar surface of the kidney (16/70 versus 0/70 in controls). The organ
eight and macroscopic observations in females were correlated
o non-neoplastic and neoplastic histological observations at this
ose.
.4.2. Non-neoplastic histological ﬁndings
At the interim necropsy, non-neoplastic test substance-
ssociated effects were present in the liver of males at 50 mg/kg
nd in the liver and kidneys of females at 500 mg/kg. In the
iver of males administered 50 mg/kg, histological lesions included
inimal focal cystic degeneration (3/10 versus 0/10 in controls)
nd minimal to mild focal necrosis (5/10 versus 1/10 in con-
rols). In females, histological changes in the liver were limited
o minimal to mild hepatocellular hypertrophy in all 10 females
eceiving 500 mg/kg. A slightly increased incidence and severity of
PN was also observed in interim sacriﬁce females at 500 mg/kg
Table 2).
At the terminal sacriﬁce, non-neoplastic test substance-
ssociated effects were observed histologically at the highest dose
evel in the liver of both sexes (Table 3) and, additionally, in the
idney (Tables 4), glandular stomach (limiting ridge) and tongue of
emales at the highest dose (Table 5).
In 50 mg/kg males, histopathological effects were limited to
he liver and included statistically signiﬁcant increases in the
ncidences of focal cystic degeneration, centrilobular hepatocellu-
ar hypertrophy, and centrilobular hepatocellular necrosis. These
hanges were also present in 500 mg/kg females, in addition
o low incidences of panlobular hepatocellular hypertrophy and
ndividual cell hepatocellular necrosis (Table 3). Cystic degener-
tion was characterized by the presence of multilocular cystic
paces containing ﬁnely granular or ﬂocculent material without
ndothelial or epithelial cells lining the spaces. Centrilobular hyper-
rophy, morphologically consistent with peroxisome proliferation,
as characterized by hepatocytes with red granular cytoplasm
ometimes containing small amounts of pigment compatible with
ipofuscin. Centrilobular hepatocellular necrosis was typically of
he coagulative type with strongly eosinophilic-staining cytoplasm
nd pyknotic nuclei. Panlobular hepatocellular hypertrophy was
haracterized by enlargement of hepatocytes throughout the entireliver. Individual cell necrosis was characterized by the presence of
scattered single hepatocytes with features characteristic of apopto-
sis.
Kidney changes in females at 500 mg/kg included tubular dila-
tion, edema of the renal papilla, transitional cell hyperplasia in
the renal pelvis, tubular mineralization, renal papillary necrosis
and CPN. Tubular dilation frequently occurred in an ascending pat-
tern extending from the papilla to the outer cortex, while at other
times it was  present only in the papilla. Edema of the papilla was
characterized by increased rarefaction or myxomatous change in
the papillary interstitium, sometimes with polypoid protrusions
from the lateral surface of the papilla. The edema and tubular dila-
tion were often associated with hyperplasia of the transitional cell
epithelium lining the papilla and pelvis. Small foci of tubular min-
eralization were often present and, in some animals, necrosis of the
tip of the papilla was  present.
In addition, in female rats given 500 mg/kg, statistically sig-
niﬁcant increases in hyperplasia of squamous epithelium were
observed in the nonglandular stomach (limiting ridge only) and
tongue (in association with subacute/chronic inﬂammation in the
tongue).
A statistically signiﬁcant increase (42/70 or 61%) in alveolar his-
tiocytosis was present in females at 500 mg/kg and was at the
upper end of the historical control range of 9.2–61.7% [22]. The
increased incidence of this common background lesion may  be
secondary to aspiration of dosing formulation at this high concen-
tration; however, a deﬁnitive mechanism for this increase could
not be determined.
3.4.3. Neoplastic histological ﬁndings
Neoplastic test substance-associated effects were observed his-
tologically at the highest dose level in the liver of females and,
equivocally, in the pancreas and testes of males at the highest dose
(Table 6).
Compound-related neoplastic changes occurred in the livers
of females administered 500 mg/kg and included increased inci-
dences of hepatocellular adenoma and carcinoma (Table 6). These
tumors occurred in association with the degenerative and necrotic
liver lesions observed at this dose as described above. Hepatocellu-
lar tumors and test substance-associated degenerative and necrotic
lesions were not observed in females at lower doses and the inci-
dences of hepatocellular tumors were similar in all male groups. In
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Table  2
Incidence of chronic progressive nephropathy in the kidneys of female rats treated with either 0 (control), 1, 50 or 500 mg/kg of ammonium 2,3,3,3-tetraﬂuoro-2-
(heptaﬂuoropropoxy)-propanoate for 12 months, N = 10.
Incidences and severity of chronic progressive nephropathy in the kidneys of female rats: interim sacriﬁce
Dose level (mg/kg) 0 1 50 500
Nephropathy, chronic progressive 6 4 6 9
-Minimal 5 3 4 3
-Mild 0 1 2 6
-Moderate 1 0 0 0
Table 3
Test substance-associated non-neoplastic histological lesions in the liver of male rats treated with either 0, 0.1, 1 or 50 mg/kg ammonium 2,3,3,3-tetraﬂuoro-2-
(heptaﬂuoropropoxy)-propanoate and female rats treated with either 0, 1, 50 or 500 mg/kg ammonium 2,3,3,3-tetraﬂuoro-2-(heptaﬂuoropropoxy)-propanoate for 24 months,
N  = 70.
Summary of test substance-associated non-neoplastic ﬁndings in the liver of male and female rats: terminal sacriﬁce
Males
Dose level (mg/kg) 0 0.1 1 50
Degeneration, cystic, focal 24 24 19 42*
Hypertrophy, hepatocyte, centrilobular 0 0 0 7*
Necrosis, hepatocytes, centrilobular 1 0 1 5*
Females
Dose level (mg/kg) 0 1 50 500
Degeneration, cystic, focal 2 2 2 14*
Hypertrophy, hepatocyte, centrilobular 0 0 3 65*
Hypertrophy, hepatocyte, panlobular 0 0 0 3*
















2Necrosis, individual hepatocyte 0 
* Signiﬁcantly different from control (p < 0.05).
ales administered 50 mg/kg, a statistically signiﬁcant increase in
he combined incidence of pancreatic acinar cell adenomas and car-
inomas was seen (Table 6), but neither the incidence of adenoma
r carcinoma alone was statistically increased, although the inci-
ence of carcinomas (2.9%) was slightly outside the historical range
f 0–1.7% [21]. In addition, the incidence of acinar cell hyperplasia
as not signiﬁcantly different from controls in any treated male
roups. However, based on the known PPAR agonist activity of
he test compound, the marginal increase in pancreatic acinar cell
umors at this dose provides equivocal evidence of a test substance-
able 4
est substance-associated non-neoplastic histological lesions in the kidney of female 
heptaﬂuoropropoxy)-propanoate for 24 months, N = 70.
Summary of test substance-associated non-neoplastic ﬁndings in the kidneys of female
Dose level (mg/kg) 0 
Dilation, tubular 4 
Edema, papilla 4 
Hyperplasia, transitional cell 6 
Mineralization, tubular 25 
Necrosis, papillary 0 
Nephropathy, chronic progressive 39 
* Signiﬁcantly different from control (p < 0.05).
able 5
est substance-associated non-neoplastic histological lesions in the nonglandular stoma
,3,3,3-tetraﬂuoro-2-(heptaﬂuoropropoxy)-propanoate for 24 months, N = 70.
Summary of test substance-associated non-neoplastic ﬁndings in the nonglandular stom
Dose level (mg/kg) 0 
Stomach, nonglandular
Hyperplasia, epithelial, limiting ridge 0 
Tongue
Hyperplasia, squamous cell 2 
Inﬂammation, subacute/chronic 3 
* Signiﬁcantly different from control (p < 0.05).0 0 3*
associated effect. Incidences of proliferative acinar cell lesions in
males receiving 0.1 and 1 mg/kg were similar to controls and no
acinar cell adenomas or carcinomas were present in females at any
dose.
The incidence of Leydig cell adenomas (11.4%) was increased
above historical control ranges for this tumor (0–8.3%) [21] in
males administered 50 mg/kg, although this increase was not stat-
ically signiﬁcant compared to controls. In addition, a Leydig cell
adenoma was  present in 1 male at the interim necropsy in the
50 mg/kg group. The incidence of Leydig cell hyperplasia was also
rats treated with either 0, 1, 50 or 500 mg/kg ammonium 2,3,3,3-tetraﬂuoro-2-








ch and tongue of female rats treated with either 0, 1, 50 or 500 mg/kg ammonium
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Table  6
Test substance-associated neoplastic histological lesions in the liver, pancreas and testes of male rats treated with either 0, 0.1, 1 or 50 mg/kg ammonium 2,3,3,3-tetraﬂuoro-2-
(heptaﬂuoropropoxy)-propanoate and the liver and pancreas of female rats treated with either 0, 1, 50 or 500 mg/kg ammonium 2,3,3,3-tetraﬂuoro-2-(heptaﬂuoropropoxy)-
propanoate for 24 months, N = 70.
Summary of test substance-associated neoplastic ﬁndings in male and female rats: terminal sacriﬁce
Males
Dose level (mg/kg) 0 0.1 1 50
Liver
Hepatocellular adenoma 1 2 1 1
Hepatocellular carcinoma 1 0 0 2
Pancreas
Acinar cell adenoma 0 1 0 3
Acinar cell carcinoma 0 0 0 2
Combined adenoma/carcinoma 0 1 0 5*
Testes
Leydig cell tumor 4 4 1 8
Females
Dose  level (mg/kg) 0 1 50 500
Liver
Hepatocellular adenoma 0 0 0 11*
Hepatocellular carcinoma 0 0 0 4*
Pancreas
Acinar cell adenoma 0 0 0 0
































rCombined adenoma/carcinoma 0 
* Signiﬁcantly different from control (p < 0.05).
ncreased above historical control range in this group at terminal
acriﬁce (also 0–8.3%; [22]; although again, this incidence was  not
tatistically signiﬁcant versus controls. However, comparison to
ithin-study controls was complicated by the fact that controls had
 relatively high incidence of Leydig cell hyperplasia (10%). Based
n the above considerations and the known activity of PPAR ago-
ists to produce Leydig cell hyperplasia and adenomas in rats, the
elationship to the test compound for these lesions was considered
quivocal in this study.
All other ﬁndings were considered to represent the spontaneous
ccurrence of neoplasms commonly seen in rats of this strain and
ge.
. Discussion
Doses employed in this study were designed to and did meet the
xpectations stated below based on information gathered from pre-
ious shorter-term repeated dose studies. The high dose (50 mg/kg
n males, 500 mg/kg in females) did produce adverse effects on a
umber of parameters without producing excessive toxicity which
ight affect survival. Seven females in the 500 mg/kg group died
rom papillary necrosis of the kidney but overall survival in this
roup was similar to that of the other test groups and the controls.
he intermediate dose (1 mg/kg in males, 50 mg/kg in females) was
elected to either produce slight to minimal effects on target tis-
ues and organs (liver and kidney) and/or to be a no-observed
dverse effect level (NOAEL), which it was found to be. The low
ose (0.1 mg/kg in males, 1 mg/kg in females) was  projected and
lso found to be a NOAEL in both sexes.
No unusual clinical signs were observed in any of the test groups
uring the course of the study. Body weights among females in the
00 mg/kg group were signiﬁcantly reduced, being up to 20% lower
han those of the controls. No body weight differences were seen
mong the male test groups. Food consumption in all test groups
as unchanged; however, because of the weight gain depression,
emales in the 500 mg/kg group showed lower food efﬁciencies.
Females receiving 500 mg/kg had mild but adverse decreases in
ed cell mass parameters at all time points tested. These changes0 0 0
were associated with an appropriate increase in reticulocytes and
were not accompanied by changes in erythrocyte morphology. Sim-
ilar decreases in red cell mass parameters were also present in
males receiving 50 mg/kg at the 3 and 6 month intervals. How-
ever, in males, the decreases were small, transient (there was  no
statistically signiﬁcant difference at 12 months), did not induce a
statically signiﬁcant increase in reticulocytes, and values in indi-
vidual animals were similar to controls. Thus, the changes observed
in 50 mg/kg males were considered to be related to treatment but
were not considered adverse. This collection of ﬁndings suggests
red cell loss or hemolysis, although the exact mechanisms involved
are unknown. Peroxisome proliferators have been shown to affect
iron metabolism, and this mechanism has been hypothesized to be
the possible cause of the mild anemia sometimes seen in humans
and rats that receive these compounds [14,15]. No changes in leuko-
cyte numbers or differential counts were seen and coagulation
parameters were normal in all test groups.
Clinical chemistry evaluations among males receiving 50 mg/kg
revealed mild but adverse increases in enzymes indicative of liver
injury, including alkaline phosphatase, alanine aminotransferase,
aspartate aminotransferase, and sorbitol dehydrogenase. These
enzyme changes correlated with microscopic ﬁndings in the liver
which consisted of minimal cystic degeneration and minimal to
mild focal necrosis. Transient, minimal increases in alkaline phos-
phatase, unassociated with increases in other liver injury-speciﬁc
enzymes, were also present in males at this dose level at 3 and 6
months; however, this increase was likely due to hepatic enzyme
induction as the test substance has been demonstrated previously
to increase total P450 enzyme activity in male rats at 30 mg/kg
[12]. These liver enzyme changes were not seen in the male groups
receiving either 0.1 or 1 mg/kg or in any of the female test groups.
In addition, a small increase in serum albumin and a decrease
in serum globulin were seen in males in the 50 mg/kg group
and females in the 500 mg/kg group which led to increases in
the albumin/globulin ratio. Slight changes in these serum protein
components were also seen in males given 1 mg/kg and females
given 50 mg/kg. The test chemical is a peroxisome proliferator
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esponse to PPAR activation [8]. Peroxisome proliferators are
nti-inﬂammatory, producing decreases in acute phase proteins
which contribute to the globulin fraction) and increases in the neg-
tive acute phase protein, albumin. No adverse biological outcomes
ave been associated with such changes in these serum proteins.
herefore, the statistically signiﬁcant changes in albumin/globulin
atio in these groups were considered to be test article-related but
onadverse based on the minimal nature of the changes and lack
f association with known adverse outcomes.
The minimal diuresis observed in females that received
00 mg/kg at 6 and 12 months was not associated with changes
n kidney-related chemistry parameters. This diuresis may  be cor-
elated to an increase in the incidence and severity of CPN observed
n this group at the 1-year sacriﬁce (Table 1).
Liver weights were increased in high dose male and female rats
t the interim sacriﬁce and in high dose females only at terminal
acriﬁce. Microscopic evaluation of the liver revealed changes only
n the high dose males and females. These changes occurred at both
he terminal sacriﬁce and, in a less progressed form, at the interim
acriﬁce and consisted of microscopic observations including focal
ystic degeneration, centrilobular (and panlobular in females only)
epatocellular hypertrophy, centrilobular hepatocellular necrosis,
nd individual cell necrosis (females only). In addition, the inci-
ences of both adenoma and carcinoma in the liver exceeded
he historical control range in females administered 500 mg/kg
only a few hepatocellular tumors occurred in males with the inci-
ence being essentially the same between the controls and the test
roups) and the increased incidences of hepatocellular tumors in
emales occurred in association with degenerative/necrotic liver
hanges. This battery of liver changes is consistent with PPAR
ctivation.
Other non-neoplastic microscopic observations included ﬁnd-
ngs in the kidneys of females at 500 mg/kg at both the interim (in a
ess severe form) and terminal sacriﬁces, and included tubular dila-
ion, edema of the renal papilla, transitional cell hyperplasia in the
enal pelvis, tubular mineralization, renal papillary necrosis, and
PN. In addition, the nonglandular stomach (limiting ridge only)
nd the tongue had statistically signiﬁcantly increased incidences
f hyperplasia of squamous epithelium in females at 500 mg/kg at
he terminal sacriﬁce only. The lesion in the tongue was  associated
ith subacute/chronic inﬂammation.
In males administered 50 mg/kg, the incidences of pancreatic
cinar cell adenoma/carcinoma combined, but not adenoma or
arcinoma alone, were statistically signiﬁcantly increased and the
ncidence of carcinoma was slightly outside the historical control
ange. Since pancreatic acinar cell hyperplasia and adenoma in
ats occur along a continuum, the incidence of acinar cell hyper-
lasia would have been expected to be increased if a test-article
elated increase in acinar cell adenoma was found. However, the
ncidences of acinar cell hyperplasia were not signiﬁcantly differ-
nt from controls in any of the treated male groups. Based on these
onsiderations, and the known PPAR agonist activity of the test
rticle, the marginal increase in pancreatic acinar cell tumors in this
roup provides equivocal evidence of a test article-related effect.
The incidences of Leydig cell adenoma of the testes were
ncreased above historical control range in the 50 mg/kg group at
erminal sacriﬁce, although this ﬁnding was not statistically signif-
cant. In addition, a single Leydig cell adenoma was  also present in
 male from this group at the interim sacriﬁce. Incidences of Leydig
ell hyperplasia were also elevated in this group above historical
ontrol range, although this, too, was not statistically signiﬁcant
ompared to controls. Since PPAR agonists are known to produce
roliferative Leydig cell lesions (hyperplasia and adenoma) in the
estes of rats, a relationship to treatment for these ﬁndings in the
0 mg/kg group cannot be ruled out. Reports 2 (2015) 939–949
The test chemical belongs to a class of compounds known
as peroxisome proliferators (PPAR agonists) which are known
to produce liver, pancreatic, and testicular tumors in rats and
liver tumors in mice [3,16]. However, these compounds have not
been shown to be carcinogenic in other species including humans
[16,7]. Based on the extensive research into the comparative biol-
ogy of peroxisome proliferator-induced hepatic carcinogenesis, the
induction of liver tumors in rodents by non-genotoxic peroxisome
proliferators (this compound was shown to be inactive in a bat-
tery of genotoxicity assays) is not considered relevant to humans
[23,7,17]. While there is less deﬁnitive mechanistic data on the role
PPAR plays in the induction of pancreatic acinar cell tumors in
rats, the available data involving altered bile ﬂow and increased
cholecystokinin suggests that this mode of action is also likely to be
non-relevant for humans [16]. While less robust, research consid-
ering comparative biology and mechanism of action of Leydig cell
tumor induction in rodents by a wide variety of chemical classes
suggests these tumors most likely have low relevance to humans
[25,6].
The ﬁndings of this study with this ﬂuorochemical polymeriza-
tion processing aid can be compared to the results from similar
studies with other ﬂuorochemical polymerization processing aids
(and PPAR agonists). The perﬂuorinated C6 chain chemical, per-
ﬂuorohexanoic acid (PFHxA), showed no evidence of an adverse
effect in male rats given oral doses of up to 100 mg/kg for 2
years [18]. Females given either 5, 30, or 200 mg/kg showed a
dose-related decrease in survival and, at 200 mg/kg, had kidney
lesions characterized by papillary necrosis and tubular degener-
ation. No evidence for a tumorigenic response was  found. For
a sulfonated ﬂuorochemical, perﬂuorooctane sulfonate (PFOS),
when fed in the diet of rats for 2 years at doses equivalent
to approximately 0.02, 0.1, 0.2, and 1 mg/kg, the primary organ
affected was  the liver with changes consisting of hepatocellular
centrilobular hypertrophy, eosinophilic granules, and vacuolation
[27]. Neoplastic lesions consisted of an increase of hepatocellu-
lar adenomas in male rats; females showed no increase in the
incidence of neoplasia. With the ammonium salt of perﬂuorooc-
tanoic acid (APFO), when fed for 2 years to male and female
rats at doses approximately equivalent to 1.5 and 15 mg/kg, the
liver was the target organ with an increase in the incidence of
hepatocellular hypertrophy, monocellular inﬁltration, and hepato-
cellular vacuolation [5]. The neoplastic changes in this study were
restricted to Leydig cell adenomas of the testes. In a follow-up
mechanistic study, male rats treated at 300 ppm of APFO for 2
years (equivalent to a daily dose of 15 mg/kg) showed increased
tumor incidences in the liver (hepatocellular adenomas), pan-
creas (acinar cell adenomas), and testes (Leydig cell adenomas)
[4].
The neoplastic changes found with this ﬂuorochemical are con-
sistent with many of those seen with the compounds above and
with other peroxisome proliferating chemicals, such as cloﬁbrate
[26], HCFC-123 [19], gemﬁbrozil, and diethyl-hexyl phthalate [6],
when tested in rodents. Although hepatocellular adenomas were
not identiﬁed in males in this study, the neoplastic pattern is sim-
ilar to that seen in rats administered APFO but was seen at a
dose somewhat higher (50 versus 15 mg/kg). In female rats, no
increase in liver neoplasia was reported with APFO while this
chemical produced an increase in both adenomas and carcinomas,
but the response was  seen only when the dose was consider-
ably higher (500 versus 15 mg/kg) than the dose used in the APFO
study.Acknowledgement
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